Celecoxib reduces brain dopaminergic neuronaldysfunction, and improves sensorimotor behavioral performance in neonatal rats exposed to systemic lipopolysaccharide by Asuka Kaizaki et al.
RESEARCH Open Access
Celecoxib reduces brain dopaminergic
neuronaldysfunction, and improves sensorimotor
behavioral performance in neonatal rats exposed
to systemic lipopolysaccharide
Asuka Kaizaki1,3, Lu-Tai Tien2, Yi Pang1, Zhengwei Cai1, Sachiko Tanaka3, Satoshi Numazawa3, Abhay J Bhatt1
and Lir-Wan Fan1*
Abstract
Background: Cyclooxygenase-2 (COX-2) is induced in inflammatory cells in response to cytokines and pro-inflammatory
molecules, suggesting that COX-2 has a role in the inflammatory process. The objective of the current study was to
examine whether celecoxib, a selective COX-2 inhibitor, could ameliorate lipopolysaccharide (LPS)-induced brain
inflammation, dopaminergic neuronal dysfunction and sensorimotor behavioral impairments.
Methods: Intraperitoneal (i.p.) injection of LPS (2 mg/kg) was performed in rat pups on postnatal Day 5 (P5), and
celecoxib (20 mg/kg) or vehicle was administered (i.p.) five minutes after LPS injection. Sensorimotor behavioral tests
were carried out 24 h after LPS exposure, and brain injury was examined on P6.
Results: Our results showed that LPS exposure resulted in impairment in sensorimotor behavioral performance and
injury to brain dopaminergic neurons, as indicated by loss of tyrosine hydroxylase (TH) immunoreactivity, as well as
decreases in mitochondria activity in the rat brain. LPS exposure also led to increases in the expression of α-synuclein
and dopamine transporter proteins and enhanced [3H]dopamine uptake. Treatment with celecoxib significantly reduced
LPS-induced sensorimotor behavioral disturbances and dopaminergic neuronal dysfunction. Celecoxib administration
significantly attenuated LPS-induced increases in the numbers of activated microglia and astrocytes and in the
concentration of IL-1β in the neonatal rat brain. The protective effect of celecoxib was also associated with an
attenuation of LPS-induced COX-2+ cells, which were double labeled with TH + (dopaminergic neuron) or glial fibrillary
acidic protein (GFAP) + (astrocyte) cells.
Conclusion: Systemic LPS administration induced brain inflammatory responses in neonatal rats; these inflammatory
responses included induction of COX-2 expression in TH neurons and astrocytes. Application of the COX-2 inhibitor
celecoxib after LPS treatment attenuated the inflammatory response and improved LPS-induced impairment, both
biochemically and behaviorally.
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Background
In humans, the timing of maternal infection during preg-
nancy appears to play a crucial role in the neurode-
velopmental responses/outcomes of offspring, and late
gestational infection has been reported to induce perseve-
rative behavior, which is implicated in schizophrenia and
autistic spectrum disorders [1]. Human fetal brain develop-
ment at late gestation roughly corresponds to the early
postnatal period in rats (postnatal Day 7 (P7) in rats equals
roughly the time of birth in humans) [2]. Our recent stu-
dies have shown that neonatal exposure to lipopolysaccha-
ride (LPS) through an intracerebral (i.c.) injection in the rat
brain (at P5, relevant to human intrauterine infection in late
gestation) can produce brain inflammation, nigrostriatal
dopaminergic injury and neurobehavioral dysfunction [3-8].
LPS, a component of the cell wall in gram-negative bac-
teria, is responsible for most of the inflammatory effects of
infection from gram-negative bacteria. LPS has been detec-
ted in the amniotic fluid [9]. Thus, it is possible that LPS
may reach the fetal brain during maternal infection.
Microglia have been identified as the major LPS-
responsive cells in the central nervous system (CNS)
[10]. Activation of microglia plays a critical role in peri-
natal i.c. LPS-induced dopaminergic neuronal injury in
the rat brain [4,5,7,8]. Interaction of microglial cells with
apoptotic neurons has been reported to selectively pro-
mote cyclooxygenase-2 (COX-2) expression, and COX-2
may mediate microglial activation and may play a key
role in amplifying the inflammatory response with toxic
effects [11,12]. In the CNS, COX-2 may have a physio-
logical role; however, COX-2 is induced in inflammatory
cells in response to cytokines and pro-inflammatory
molecules, suggesting that COX-2 has a role in the
inflammatory processes [11,13]. COX-2 is primarily re-
sponsible for prostanoid production in acute and
chronic inflammatory processes, and its inhibition leads
to anti-inflammatory effects [11,13]. COX-2 has also
been hypothesized to be involved in many neurodegen-
erative diseases, such as multiple sclerosis, amyotrophic
lateral sclerosis, Parkinson’s disease, Creutzfeldt-Jakob
disease and Alzheimer’s disease [13].
Celecoxib is a selective COX-2 inhibitor and the safest
COX-2 inhibitor in terms of cardiovascular safety data
[14]. The neuroprotective action of celecoxib has been ob-
served in the LPS-induced nigrostriatal neurodegeneration
[15] and 6-hydroxydopamine (6-OHDA)-induced progres-
sive dopaminergic neuron degeneration in a rat model of
Parkinson’s disease [16]. The objective of the present study
was to investigate whether systemic LPS exposure (at P5)
through an i.p. injection also induced central inflamma-
tion, brain dopaminergic neuronal injury and sensori-
motor behavioral deficits in our neonatal rat model
whether celecoxib offered protection against LPS-induced
brain inflammation and dopaminergic neuronal injury and




Unless otherwise stated, all chemicals used in this study
were purchased from Sigma (St. Louis, MO, USA). Mo-
noclonal mouse antibodies against β-amyloid precursor
protein (APP), glial fibrillary acidic protein (GFAP), and
α-synuclein were purchased from Millipore (Billerica,
MA, USA; APP and GFAP) and BD Bioscience (San Jose,
CA, USA; α-synuclein). Polyclonal rabbit antibodies
against tyrosine hydroxylase (TH) and ionized calcium
binding adapter molecule 1 (Iba1) were obtained from
Millipore and Wako Chemicals USA (Irvine, CA, USA),
respectively. Polyclonal rat antibodies against dopamine
transporter (DAT) and polyclonal goat antibodies against
COX-2 were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). [3H]Dopamine ([3H]DA, specific
activity 34.6 Ci/mmol) was purchased from PerkinElmer
(Boston, MA, USA). Enzyme-linked immunosorbent assay
(ELISA) kits for immunoassay of rat interleukin-1β
(IL-1β) and tumor necrosis factor-α (TNFα) were pur-
chased from R&D Systems (Minneapolis, MN, USA).
Animals
Timed pregnant Sprague–Dawley rats arrived in the
laboratory on Day 19 of gestation. Animals were
maintained in a room with a 12-h light/dark cycle and at
constant temperature (22 ± 2°C). The day of birth was
defined as postnatal Day 0 (P0). After birth, the litter
size was adjusted to 12 pups per litter to minimize the
effects of litter size on body weight and brain size. All
procedures for animal care were conducted in accord-
ance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved
by the Institutional Animal Care and Use Committee at
the University of Mississippi Medical Center. Every ef-
fort was made to minimize the number of animals used
and their suffering.
Animal treatment
Injection of LPS (2 mg/kg i.p., from Escherichia coli,
serotype 055: B5) was performed in five-day-old Sprague–
Dawley rat pups of both sexes. The control rats were
injected with the same volume of sterile saline (0.1 mL).
All animals survived the injection. Both LPS- and saline-
injected animals were further divided into two groups:
one received an i.p. injection of celecoxib (20 mg/kg), and
the other group received an i.p. injection of vehicle.
Celecoxib (20 mg/kg) was dissolved in 20% dimethyl sulf-
oxide (DMSO) in normal saline [17,18] and administered
immediately after the LPS injection. Thirty rats (15 male
and 15 female pups) from each group were used in the
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present study. Behavioral tests were conducted in 12 rats
from each group from P5 to P6. Rats were sacrificed on
P6. Twenty-four rats from each group were sacrificed by
decapitation to collect fresh brain tissue for Western blot
analysis (six rats for each group), determination of the
mitochondrial complex I activity (six rats for each group),
ELISA assay (six rats for each group), and [3H]DA uptake
study (six rats for each group). Six additional rats from
each group were sacrificed by transcardiac perfusion with
normal saline followed by 4% paraformaldehyde for brain
section preparation. Free-floating coronal brain sections
of 40-μm thickness were prepared in a freezing microtome
(Leica, SM 2000R, Wetzlar, Germany) for immunohisto-
chemistry staining.
Behavioral testing
Behavioral tests were performed as described by Fan et al.
[4], with modifications. The developmental test battery
that was used was based on previously documented tests
for neurobehavioral toxicity [19,20]. Behavioral tests, in-
cluding the righting reflex and negative geotaxis test, were
performed for all rat pups from P5 to P6.
Righting reflex
This test is believed to be a reflection of muscle strength
and subcortical maturation [20,21]. Pups were placed on
their backs, and the time required to turn over on all
four feet and touch the platform was measured. The
cut-off time was 60 s.
Negative geotaxis
This test is believed to test reflex development, motor
skills, vestibular labyrinth and cerebellar integration
[19,20]. Rats were placed on a 15° incline with their heads
pointing down the slope and had to turn to face upward
and begin to crawl up the slope. Each pup was given three
trials a day, and the time spent to make a turn of 180° up-
ward was recorded. The cut-off time was 60 s.
Immunohistochemistry
Brain injury was estimated based on the results of immu-
nohistochemistry in consecutive brain sections prepared
from rats sacrificed one day (P6) after LPS injection. For
immunohistochemistry staining, primary antibodies were
used in the following dilutions: TH and Iba1, 1:500; GFAP,
1:200; and APP and COX-2, 1:100. TH was used to detect
dopaminergic neurons in the substantia nigra (SN). The
amount of APP, a membrane-spanning glycoprotein, in
normal axons and neurons is not enough to be detected,
but the accumulation of APP can be detected as an early
sign of axonal and neuronal lesions [22,23]. Microglia
were detected using Iba1 immunostaining, which recog-
nizes both resting and activated microglia. GFAP was used
to detect astrocytes. COX-2 provided selective staining of
inducible cyclooxygenase. Sections were incubated with
primary antibodies at 4°C overnight and further incubated
with fluorescence-conjugated secondary antibodies (Alexa
Fluor 555, 1:500 or Alexa Fluor 488, 1:200; Jackson
Immunoresearch, West Grove, PA, USA) for 1 h in
the dark at room temperature. DAPI (40,6-diamidino-
2-phenylindole) (100 ng/mL) was used simultaneously to
identify nuclei in the final visualization. Sections incubated
in the absence of primary antibodies were used as negative
controls. When double-labeling was required, primary
antibodies from different hosts were used in combination
with appropriate secondary antibodies, which were raised
against the immunoglobulin from the corresponding host.
The resulting sections were examined under a fluorescent
microscope (BX60, Olympus America Inc., Center Valley,
PA, USA) at appropriate wavelengths.
Immunoblotting analysis
Protein expression of DAT and α-synuclein was deter-
mined in P6 rat brains by Western blotting according to
the methods of Fan et al. [7,8] and Hadlock et al. [24],
with modifications. One day after LPS injection (P6),
brains were quickly removed, and tissues were frozen in li-
quid nitrogen and stored at −80°C. Tissues were homoge-
nized in an extraction buffer (Biosource, Camarillo, CA,
USA), and a mixture of protease inhibitors (Calbiochem,
La Jolla, CA, USA) and 1 mM phenylmethylsulfonyl fluor-
ide (PMSF) was added, accompanied by application of a
Sonic Dismembrator (Fisher Scientific, Suwanee, GA,
USA) three times for 10 s each. Protein levels of homoge-
nates were determined by the Bradford method. The ho-
mogenates were diluted 1:2 (v/v) with Laemmli sample
buffer. Equal quantities of protein (10 μg/10 μL) were
loaded into each well of a 4% to 20% SDS-polyacrylamide
gradient gel (MINI-PROTEAN TGX, 4 to 20%, Bio-Rad
Laboratories, Hercules, CA, USA). The separated proteins
were transferred electrophoretically to polyvinylidene
difluoride (PVDF) membranes (Bio-Rad Laboratories) at
100 V for 1 h. The blots were incubated with a blocking
solution containing 5% nonfat milk and 0.1% Tween-20 in
Tris-buffered saline (TBS) for 1 h before incubation with
the primary antibody (1:1,000) in the blocking solution
overnight at 4°C. The blots were then incubated with
peroxidase-conjugated antibodies in blocking solution
(1:4,000) for 1 h at room temperature. Immunoreactivity
was detected by the Enhanced Chemiluminescence Plus
or Advanced ECL system (GE Healthcare, Piscataway, NJ,
USA). Images were acquired with the Chemidoc MP Im-
aging System followed by quantification using Image Lab
software (both from Bio-Rad Laboratories). To ensure that
equal amounts of protein were applied to the immuno-
blot, the membranes were stripped with a stripping buffer
(Thermo Scientific, Rockford, IL, USA) and re-probed for
β-actin (1:4,000, Sigma) to normalize the results.
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Synaptosomal [3H]DA (dopamine) uptake
Uptake of [3H]DA was determined according to the
methods of Hadlock et al. [24] and Nickell et al. [25],
with modifications. One day after LPS injection (P6),
brain tissues were homogenized in ice-cold 0.32 M su-
crose (50 mM Tris buffer, pH 7.4) and centrifuged (800 × g
for 12 minutes; 4°C). The supernatant (S1) was then
centrifuged (20,000 × g for 15 minutes; 4°C), and the
resulting pellets (P2, synaptosomes) were resuspended in
ice-cold water at concentrations of 2 mg/mL to lyse the
synaptosomal membranes. Synaptosomal fractions were
chilled at 4°C until DA uptake experiments commenced.
Assays were performed in duplicate with a final volume of
250 μL. Aliquots of 25 μL synaptosomal fractions (50 μg of
P2 protein) were added to tubes containing assay buffer
(126 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 16 mM
NaH2PO4, 1.4 mM MgSO4, 11 mM glucose and 1 mM as-
corbic acid, pH 7.4) and 1 μM pargyline and then incu-
bated at 37°C for five minutes. Nonspecific uptake was
determined in the presence of 10 μM nomifensine. Sam-
ples were placed on ice, and 25 μL of 0.1 μM [3H]DA (10
nM final concentration) was added to each tube, after
which accumulation was permitted to proceed for five mi-
nutes at 37°C. DA concentration and time of uptake were
chosen based on the reports by Hadlock et al. [24] and
Nickell et al. [25]. The reaction was terminated by the
addition of 250 μL ice-cold assay buffer and subsequent
filtration, followed immediately by the washing two times
of ice-cold assay buffer. Radioactivity retained by the
filters was counted using a liquid scintillation counter
(PerkinElmer). Nonspecific uptake, defined as DA up-
take in the presence of 10 μM nomifensine, was
subtracted from total uptake to define DAT-mediated
specific uptake.
Determination of mitochondrial complex I activity
Complex I activity was determined by a spectrophotome-
tric assay based on the quantification of the rate of oxida-
tion of the complex I substrate NADH to ubiquinone as
described by Champy et al. [26] and Hoglinger et al. [27],
with minor modifications. Brain tissues from each pup
were collected at 6 or 24 h after LPS injection. The frozen
brain tissue was homogenized mechanically, sonicated on
ice in 10 mM Tris–HCl buffer (pH 7.2) containing 225
mM mannitol, 75 mM saccharose and 0.1 mM EDTA,
and then centrifuged (600 × g) for 20 minutes at 4°C, to
obtain post-nuclear supernatants. The optical density of
the supernatants (40 μg sample protein) in 1 mL an assay
mixture was spectrophotometrically recorded at a wave-
length of 340 nm for 200 s at 37°C. The assay mixture was
a potassium phosphate buffer (25 mM, pH 7.5) containing
2 mM potassium cyanide, 5 mM magnesium chloride,
2.5 mg/mL bovine serum albumin, 2 μM antimycin A,
100 μM decylubiquinone and 300 μM NADH. The
proportion of NADH oxidation sensitive to an excess of
rotenone (10 μM) was attributed to the activity of com-
plex I. This procedure minimizes the dissociation of rote-
none from complex I because of the use of small buffer
volumes, maintenance at low temperatures, and rapid
analysis. The specific activity (nmol NADH oxidation/
min/mg protein) of complex I (NADH-ubiquinone oxido-
reductase) was calculated using a molar extinction coef-
ficient ε340nm = 6.22 mM
-1 cm-1 [28]. Enzyme activities
were expressed as nmol/min/mg of brain tissue. Complex
I activity was calculated as follows: Complex I activity =
(Rate (min-1)/ ε340nm (6.22 mM
-1 cm-1))/ 0.040 mg.
Determination of IL-1β and TNFα protein by ELISA
Two major pro-inflammatory cytokines, IL-1β and TNFα,
were determined by ELISA as previously described [6,29].
Briefly, brain tissues from each pup were collected 24 h
after LPS injection, when the LPS-stimulated increase in in-
flammatory cytokines in the rat brain reached a peak value
[30]. Brain tissues were homogenized by sonication in 1
mL ice-cold PBS (pH 7.2) and centrifuged at 12,000 × g for
20 minutes at 4°C. The supernatant was collected, and the
protein concentration was determined by the Bradford
method. ELISA was performed following the manufac-
turer’s instructions, and data were acquired using a 96-well
plate reader (Bio-Tek Instruments, Inc., Winooski, VT,
USA). The cytokine contents were expressed as pg cyto-
kine/mg protein.
Quantification of data and statistics
Brain sections at the bregma level and the midbrain sec-
tions at a level one-third rostral from the lambda to the
bregma were used for determination of the most patho-
logical changes. Most immunostaining data were quanti-
fied by the counting of positively stained cells. When the
cellular boundary was not clearly separated, numbers of
DAPI-stained nuclei from the superimposed images
were counted as the cell number. Three digital micro-
scopic images were randomly captured in each of the
three sections, and the number of positively stained cells
in the three images was counted and averaged (cells/mm2).
The mean value of cell counts from three brain sections
was used to represent one single brain. For convenience
of comparison among the treatment groups, results
were standardized as the average number of cells/mm2.
APP or COX-2 staining was quantified using National
Institutes of Health (NIH) image software to determine
the percentage area containing APP- or COX-2-positive
staining in the entire area of the captured image [31]. In
response to LPS challenge, the number of Iba1+ microglia
and GFAP + astrocytes increases, and the soma of these
cells become larger. In addition to cell density, Iba1 or
GFAP immunoreactivity was also quantified by calculating
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the percentage area of the whole image containing Iba1 or
GFAP immunostaining [7,8].
The behavioral data were presented as the mean ± SEM
and analyzed by one-way ANOVA followed by the
Student-Newman-Keuls test. Data from immunostaining,
immunoblotting analysis, [3H]DA uptake, mitochondrial
complex I activity and ELISA assay were presented as
the mean ± SEM and analyzed by one-way ANOVA
followed by the Student-Newman-Keuls test. Results
with a P-value of less than 0.05 were considered sta-
tistically significant.
Results
Celecoxib improved sensorimotor behavioral deficits
induced by LPS exposure
Compared with the control group, LPS-injection in P5
rats resulted in sensorimotor behavioral deficits at P6
(Figure 1A, B). Celecoxib treatment significantly im-
proved sensorimotor behavioral performance following
LPS exposure (Figure 1A, B).
Righting reflex
The LPS-injected group exhibited significantly longer
mean latency times as compared to the control group at
P6 (P <0.05; Figure 1A). Celecoxib treatment signifi-
cantly shortened the LPS-induced increase in righting
reflex latency (P <0.05), and there was no difference in
righting reflex between the control and the LPS +
celecoxib groups (Figure 1A).
Negative geotaxis
As shown in Figure 1B, the LPS-injected group exhibited
significantly longer mean latency times for negative geo-
taxis along a 15° incline as compared to the control
group at P6 (P <0.05). Celecoxib treatment significantly
shortened the duration of the LPS-induced increase in
negative geotaxis latency (P <0.05; Figure 1B).
Celecoxib decreased LPS-induced dopaminergic neuronal
and axonal damage
Positive staining for TH was used to detect dopaminergic
neurons in the SN. In the P6 control rat brain, TH-positive
cells were more predominant in the compact and lateral
regions of the SN (Figure 2A, G). As shown in Figure 2B,
neonatal systemic LPS exposure suppressed TH expression
in the SN, as indicated by the reduced number of TH +
neurons in the P6 rat brain (P <0.05; Figure 2B, G). This
result was similar to the reduction of TH + staining in-
duced by i.c. LPS injection that we reported previously [5].
Celecoxib treatment attenuated the LPS-induced reduc-
tion in the number of TH-positive neurons (P <0.05;
Figure 2C, G).
Up-regulation of APP, an early sign of axonal and neu-
ronal lesions [22,23], was determined by immunostaining
in the striatum of P6 rats. As shown in Figure 2D, weak
expression of APP was barely detectable in the control rat
brain. Beaded APP immunostaining was observed in the
LPS-exposed brain (P <0.05; Figure 2E, H). Celecoxib
treatment attenuated the LPS-induced injury to axons in
the striatum, as indicated by weak APP immunostaining,
which was similar to that observed in control rats
(P <0.05; Figure 2F, H).
Celecoxib attenuated LPS-induced neuronal dysfunction
and decreases in mitochondrial complex I activity
Neonatal systemic LPS exposure not only increased the
amount of DAT and α-synuclein protein (P <0.05;
Figure 3Aa, b), but also increased [3H]DA uptake
(P <0.05; Figure 3B). Dopamine uptake was measured by
total [3H]DA uptake into brain synaptosomes, as de-
scribe in the Methods section. These results revealed
that LPS exposure may affect DAT function. Treatment
with celecoxib significantly attenuated LPS-induced
increases in the expression of α-synuclein and DAT pro-
teins, as well as [3H]DA uptake (P <0.05; Figure 3A, B).
Figure 1 Celecoxib attenuated systemic LPS-induced
neurobehavioral deficits in the rat. Celecoxib attenuated
LPS-induced elongation of mean latency times in righting
reflex (A) and negative geotaxis (B).
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Mitochondrial complex I activity was measured as the
amount of NADH oxidized per minute per milligram of
protein in homogenates of whole brains of rats at 24 h
after LPS injection. Systemic LPS exposure reduced en-
zymatic activity of mitochondrial complex I in 24 h (P6;
P <0.05; Figure 3C). Celecoxib treatment attenuated the
LPS-induced decrease in mitochondrial complex I activi-
ty in P6 rat brains (P <0.05; Figure 3C).
Celecoxib decreased the LPS-induced increase in
microglial activation and inflammatory responses
Activated microglia were assessed by Iba1 immunostain-
ing in the rat SN (Figure 4A–C, G, H) and striatum
(Figure 4D–H). LPS treatment triggered the activation of
microglia in the SN (Figure 4B, G, H) and striatum
(Figure 4E, G, H). In control rat brains, a few Iba1-
positive cells were detected, and most of these cells were
in a resting state with a ramified shape in both the SN
and striatum (arrows indicated in Figure 4A, D). Sig-
nificantly increased numbers of activated microglia
(Figure 4G) showing bright staining of an elongated or a
round-shaped cell body with blunt or no processes were
found in the SN and striatum (arrows indicated in
Figure 4B, E) 24 h after LPS injection (P <0.05). Iba1
staining was also quantified by measuring the percentage
area containing Iba1 immunostaining in the captured
images. Higher percentages of Iba1 immunostaining
areas were observed in the SN and striatum of neonatal
Figure 2 Representative photomicrographs of TH (A to C, SN) and APP (D to F, striatum) immunostaining in the rat brain after LPS
injection. TH positive staining was detected in the SN area (A) of the midbrain sections at a level one-third rostral from the lambda to the
bregma in the control rat brain. LPS injection caused a loss of TH positive staining (B). Celecoxib attenuated the LPS-induced loss of TH positive
staining (C). Weak APP positive staining was detectable in the brain sections at the bregma level of the control brain (D). The beaded APP
staining was found in the striatum (E) of the LPS-exposed brain. Celecoxib treatment attenuated the LPS-induced injury to axons in the striatum
(F). The scale bar shown in A represents 200 μm for A to C, or shown in D represents 50 μm for D to F. Quantitation of the number of TH
positive cells in the SN (G), and the percentage area of image that contained APP + staining in the cingulum white matter and the striatum were
performed as described in Methods. The results are expressed as the mean ± SEM of six animals in each group, and analyzed by one-way
ANOVA. *P <0.05 represents a significant difference for the LPS + Vehicle group or LPS + Celecoxib group as compared with the Saline + Vehicle
group. #P <0.05 represents a significant difference for the LPS + Celecoxib group as compared with the LPS + Vehicle group.
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LPS-exposed rat brains (Figure 4H). Celecoxib treatment
reduced the number of activated microglia and percent-
age of Iba1 immunostaining area following LPS injection
(P <0.05; Figure 4C, F–H).
Systemic exposure to LPS resulted in inflammatory
responses in the rat brain, as evidenced by the elevated
expression of a major pro-inflammatory cytokine, IL-1β
(Figure 5A). However, the concentration of TNFα in the
rat brain returned to the control level 24 h after LPS ex-
posure (Figure 5B). Treatment with celecoxib attenuated
the induction of IL-1β content by LPS (P <0.05;
Figure 5A).
Celecoxib decreased the LPS-induced increase in
astrocyte activation and COX-2 expression
Development of hypertrophic morphology and up-
regulation of intermediate filament proteins, such as
GFAP, by reactive astrocytes are perhaps the best known
hallmarks of reactive astrocytes and reactive gliosis
[32,33]. Increased expression of GFAP, an indication of
astrogliosis, was observed at the SN (Figure 6B) and stri-
atum (Figure 6E) 24 h after injection in rats exposed to
systemic LPS (Figure 6G). In control rat brains, some
GFAP-positive cells were detected, and most of these
cells were in the resting state, with fine processes
extending from the main cellular processes (arrows indi-
cated in Figure 6A, D). Significantly increased numbers
of reactive astrocytes showing hypertrophy of cellular
processes of astrocytes (GFAP + cells) were found in the
SN (arrows indicated in Figure 6B) and striatum (arrows
indicated in Figure 6E) of rat brains 24 h after LPS injec-
tion (P <0.05; Figure 6G). GFAP staining was also
Figure 3 Celecoxib attenuated the systemic LPS-induced
change in expression of DAT and α-synuclein (A), [3H]DA
uptake (B), and mitochondrial complex I enzymatic activity (C)
in the rat brain. Aa, Western blotting of protein expression of DAT
and α-synuclein in P6 rat brain. Ab, Expression of DAT (left panel of
Ab) and α-synuclein (right panel of Ab) is presented as the
percentage of expression in the control group (Saline + Vehicle).
Systemic LPS exposure increased DAT and α-synuclein expression in
P6 rat brain. Celecoxib treatment attenuated the LPS-induced
increase in expression of DAT and α-synuclein in the P6 rats. B,
Dopamine uptake was measured by total [3H]DA uptake into brain
synaptosomes and [3H]DA uptake is presented as the percentage of
data in the control group (Saline + Vehicle). LPS exposure increased
[3H]DA uptake in P6 rat brain. Celecoxib attenuated the LPS-induced
increase in total [3H]DA uptake in the P6 rats. C, LPS exposure
reduced enzymatic activity of mitochondrial complex I in 24 hours
after LPS injection. Celecoxib treatment attenuated the LPS-induced
decrease in mitochondrial complex I activity in P6 rats. The results
are expressed as the mean ± SEM of six animals in each group, and
analyzed by one-way ANOVA. *P <0.05 represents a significant
difference for the LPS + Vehicle group or LPS + Celecoxib group as
compared with the Saline + Vehicle group. #P <0.05 represents a
significant difference for the LPS + Celecoxib group as compared
with the LPS + Vehicle group.
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Figure 4 Representative photomicrographs of microglia (A to C, SN; D to F, striatum) in the rat brain after LPS injection. As shown by
Iba1 immunostaining in the SN (A) and striatum (D), a few microglia at the resting status with a small rod-shaped soma and ramified processes
(arrows indicated in A and D) were found in the control rat brain. Numerous activated microglia showing bright staining of an elongated or a
round shaped cell body with blunt or no processes (arrows indicated in B and E) were observed in the SN (B) and striatum (E) of the rat brain
with neonatal LPS exposure. Celecoxib treatment reduced the number of activated microglia stimulated by LPS in the above areas (C, F and G).
The scale bar shown in A represents 50 μm for A to F. Quantitation of the number of Iba1+ cells (G) and the percentage area of image that
contained Iba1 staining (H) in the SN and striatum were performed as described in Methods. The results are expressed as the mean ± SEM of six
animals in each group, and analyzed by one-way ANOVA. *P <0.05 represents a significant difference for the LPS + Vehicle group as compared
with the Saline + Vehicle group. #P <0.05 represents a significant difference for the LPS + Celecoxib group as compared with the LPS +
Vehicle group.
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quantified by measuring the percent area containing
GFAP immunostaining in the captured images. A higher
percentage of GFAP immunostaining area was observed
in the SN and striatum of neonatal LPS-exposed rat
brains (Figure 6H). Celecoxib treatment reduced the num-
ber of activated astrocytes and the percentage of GFAP
immunostaining area following LPS injection (P <0.05;
Figure 6C, F–H).
Neonatal systemic LPS-induced inflammatory res-
ponses were also observed, as indicated by the increase
in the percent area containing COX-2+ cells in the rat
SN (Figure 7B, D, G, J) and striatum (Figure 7J) as com-
pared to that in the control rat SN (Figure 7A, J) and
striatum (Figure 7J), respectively. Double staining
showed that most COX-2+ cells in the SN were co-
localized with GFAP + cells (Figure 7E, F), and some of
these double-labeled cells were also co-localized with
TH + neurons (Figure 7H, 7I). There were few COX-2+
cells that localized with Iba1-expressing microglia (data
not shown). Treatment with celecoxib reduced the
increase in percentage of COX-2 immunostaining area
in the rat SN and striatum following LPS injection
(P <0.05; Figure 7C, J).
Discussion
Our results indicated that, similar to i.c. LPS injection,
systemic exposure to LPS through i.p. injection in neo-
natal rats cause brain inflammatory responses and sen-
sorimotor behavioral impairment, as well as damage to
the dopaminergic system in the rat brain [3-6,29,34].
Neonatal systemic LPS exposure resulted in brain in-
flammatory responses in the rat, as indicated by an in-
creased number of activated microglia (Figure 4) and
elevated IL-1β concentrations in LPS-treated rat brains
(Figure 5A). Our previous data also show that activation
of microglia plays a critical role in perinatal i.c. LPS-
induced dopaminergic neuronal injury in rat brains
[4,5,8]. Microglia, the major resident immune cells in
the brain, have been identified as the major LPS-
responsive cells in the CNS [10]. Microglia are detect-
able in the CNS of early embryos, but the largest
population of newborn microglia emerges in late gestation
and the early postnatal period in both humans and rats
[35,36]. Thus, the LPS exposure in perinatal rat brains
(P5, relevant to human intrauterine infection in late ges-
tation) can produce substantial inflammatory responses
in the brain. LPS treatment also induced the expression
of COX-2 in cells that were double labeled with TH +
(dopaminergic neurons) or GFAP + (astrocytes) cells in
neonatal rat brains (Figure 7). Interactions between
microglial cells and apoptotic neurons have been
reported to selectively promote COX-2 expression, and
COX-2 may mediate microglial activation and may play
a key role in amplifying the inflammatory response with
toxic effects [11,12]. The current study showed that
treatment with a selective COX-2 inhibitor, celecoxib,
elicited anti-inflammatory effects, as evidenced by the
attenuation of LPS-induced increases in the number of
activated microglia and in the concentration of IL-1β in
neonatal rat brains.
Increased expression of GFAP, an indicator of astrogliosis,
was observed in the SN and striatum in rats 24 h after sys-
temic LPS exposure (Figure 6). Treatment with celecoxib
affected LPS-induced astrogliosis (Figure 6) and reduced
the number of GFAP + and COX2+ double-labeled cells in
LPS-exposed rat brains (Figure 7). Reactive astrocytes usu-
ally do not attack pathological targets, as do microglia, but
instead wall off such targets to form a syncytium of inter-
Figure 5 Celecoxib attenuated systemic LPS-stimulated
increases in inflammatory cytokine, IL-1β in the rat brain. A,
IL-1β and B, TNFα concentrations were determined by ELISA kit and
presented in the unit of pg/mg protein, as described in Methods.
Twenty-four hours following LPS injection, the brain level of IL-1β
(A) was elevated as compared with the Saline + Vehicle group.
Treatment with celecoxib attenuated induction of IL-1β content by
LPS. The results are expressed as the mean ± SEM of six animals in
each group, and analyzed by one-way ANOVA. * P <0.05 represents
a significant difference for the LPS + Vehicle group or LPS +
Celecoxib group as compared with the Saline + Vehicle group.
#P <0.05 represents a significant difference for the LPS + Celecoxib
group as compared with the LPS + Vehicle group.
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Figure 6 Representative photomicrographs of astrocytes (A to C, SN; D to F, striatum) in the rat brain after LPS injection. As shown by
GFAP immunostaining in the SN (A) and striatum (D) in the control rat brain, some GFAP positive cells were detected and most of those cells
were in resting status with fine processes extending from the main cellular processes (arrows indicated A and D). Significantly increased numbers
of reactive astrocytes showing hypertrophy of cellular processes (arrows indicated in B and E) were observed in SN (B) and striatum (E) of the rat
brain following neonatal LPS exposure. Celecoxib treatment reduced the number of reactive astrocytes stimulated by LPS in the above areas (C, F
and G). The scale bar shown in A represents 50 μm for A to F. Quantitation of the number of GFAP + cells (G) and the percentage area of image
that contained GFAP staining (H) in the SN and striatum were performed as described in Methods. The results are expressed as the mean ± SEM
of six animals in each group, and analyzed by one-way ANOVA. *P <0.05 represents a significant difference for the LPS + Vehicle group as
compared with the Saline + Vehicle group. #P <0.05 represents a significant difference for the LPS + Celecoxib group as compared with
the LPS + Vehicle group.
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connected cells, both in healthy and diseased states [32,33].
Astrocytes produce both pro-inflammatory and anti-
inflammatory responses; for example, astrocytes may stimu-
late the microglia and secrete protective factors to the
peripheral region at the same time [32]. α-Synuclein has
been shown to activate both microglia and astrocytes, and
these interactions may contribute to dopamine quinine for-
mation [37]. However, the precise mechanisms of inter-
action between astrogliosis and dopaminergic neuronal
injury are unclear, and further studies are needed.
Figure 7 Representative photomicrographs of COX-2 immunostaining (A to I, SN) in the rat brain after LPS injection. Weak COX-2
positive staining was detectable in the brain sections of control brain (A). LPS injection increased the expression of inducible cyclooxygenase, as
indicated by COX-2+ staining, in SN (B, D and G, red) and striatum (J) of P6 rat brain. Celecoxib treatment attenuated the LPS-increased COX-2+
staining in the above areas (C and J). F is a merged image of D and E. Double-labeling (yellow) showed that many COX-2 positive cells (F) were
GFAP + cells (astrocytes) (E, green). I is a merged image of G and H. Double-labeling (yellow) also showed that some COX-2 positive cells (I) were
TH + cells (dopaminergic neuron) (H, green). The scale bar in A represents 50 μm for A to I. Quantitation of the percentage area of image that
contained COX-2+ staining in the SN and striatum was performed as described in Methods. The results are expressed as the mean ± SEM of six
animals in each group, and analyzed by one-way ANOVA. *P <0.05 represents a significant difference for the LPS + Vehicle group as compared
with the Saline + Vehicle group. #P <0.05 represents a significant difference for the LPS + Celecoxib group as compared with the LPS +
Vehicle group.
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Neonatal systemic LPS exposure resulted in dopamin-
ergic system disturbances, as indicated by sensorimotor
impairments, a decrease in the number of TH + cells in
SN, and increases in the expression of α-synuclein and
DAT proteins, and an increase in [3H]DA uptake in
rat brains (Figures 1, 2, 3). Neuroinflammation and
α-synuclein dysfunction have been proposed to potentiate
each other; this may drive chronic progression of neuro-
degeneration [38]. The present study also showed that
LPS exposure induced COX-2 expression in dopaminergic
neurons of the rat SN (Figure 7). Increased COX-2 expres-
sion in dopaminergic cells under stressful conditions can
facilitate dopamine oxidation to quinone species, triggering
oxidative stress, and COX-2 overexpression in dopami-
nergic cells may also play a role in α-synuclein accumula-
tion [11,39]. Other reports have implied that α-synuclein
may modulate DAT function, and disruption of this
modulatory process may permit increased re-uptake of
high levels of intracellular dopamine by DAT, causing
profound neurotoxicity [40,41]. Moreover, α-synuclein can
associate with the inner mitochondrial membrane and
mitochondrial α-synuclein accumulation results in complex
I impairment in dopaminergic neurons and increased free
radical production [42]. The current study found that
treatment with the COX-2 inhibitor celecoxib attenuated
the LPS-induced decrease in mitochondria complex I ac-
tivity, dopaminergic injury and dopaminergic dysfunction.
Therefore, the neuroprotective effects of COX-2 inhibition
may be related to the blockade of COX-2-mediated
dopamine oxidation and the inhibition of amplifica-
tion of the inflammatory response, causing toxic effects
[11,12].
LPS may provoke a dramatic systemic response, in-
cluding up-regulation of inflammatory mediators and
procoagulant factors in the systemic circulation, and LPS
may also cause diarrhea, changes in plasma protein
binding capacity, and modulation of hepatic and/or in-
testinal microsomal cytochrome P450 (CYP) isozymes,
thereby affecting the renal excretion of drugs [43,44].
Therefore, the central neuroprotective effect of celecoxib
may result from not only direct COX-2 inhibition in the
brain, but also the effects of celecoxib on peripheral in-
flammatory responses. Other reports have indicated that
intracerebral administration of LPS in rodents induces
strong increases in COX-2 expression, mainly in astro-
glia and microglia, whereas COX-1 expression was pre-
dominantly observed in microglia and did not increase
[45]. However, it has been suggested that, owing to its
predominant localization in microglia, COX-1 may be
the major player in neuroinflammation, whereas COX-2,
which is localized in neurons, may have a major role in
models in which the neurons are directly challenged
[46]. Therefore, COX-1 preferential inhibitors also need
to be further investigated in neurodegenerative diseases.
COX-2 has been suggested to be associated with vari-
ous inflammatory parameters and is thought to be in-
volved in neurodegenerative processes, such as multiple
sclerosis, amyotrophic lateral sclerosis, Parkinson’s dis-
ease, Creutzfeldt-Jakob disease and Alzheimer’s disease
[11,13]. Celecoxib is a selective COX-2 inhibitor and has
been shown to be the safest COX-2 inhibitor in terms of
cardiovascular safety data [14]. The neuroprotective
action of celecoxib has been observed in LPS-induced
nigrostriatal neurodegeneration [15] and 6-hydroxy-
dopamine (6-OHDA)-induced progressive dopaminergic
neuron degeneration in a rat model of Parkinson’s disease
[16]. Our present results also suggested that celecoxib
may provide protection against systemic LPS exposure-
induced dopaminergic neuronal dysfunction and sensori-
motor behavioral disturbances; these protective effects are
likely associated with its anti-inflammatory properties.
However, the neuroprotective effects of celecoxib are still
controversial since celecoxib has been reported to prevent
LPS-induced cognitive impairments in mice [47], but also
to worsen spatial memory retention in rats [48]. Epidemi-
ologic evidence suggests that celecoxib may delay the on-
set of Alzheimer’s dementia [49], but there is no benefit
from celecoxib in symptomatic Alzheimer’s disease [50].
Thus, the chronic use of celecoxib may be beneficial only
in the very early stages of the Alzheimer’s disease process
[51]. Detailed mechanisms of celecoxib involvement in re-
ducing systemic LPS exposure-induced dopaminergic
neuronal dysfunction and in protection against LPS-
induced sensorimotor behavioral disturbances need fur-
ther investigation.
Conclusion
Brain inflammation induced through systemic LPS
exposure is clinically relevant, and our current findings
indicated that systemic LPS exposure (P5) through an
i.p. injection induced central inflammation; these inflam-
matory responses included induction of COX-2 expres-
sion in TH neurons and astrocytes. Our results also
suggested that application of the COX-2 inhibitor cele-
coxib after LPS injection can attenuate the inflammatory
response and improve LPS-induced impairment, inclu-
ding dopaminergic neuronal dysfunction and sensori-
motor behavioral disturbances. The current results
provide valuable information for developing strategies in
the prevention and therapeutic treatment of neurode-
generative diseases.
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